[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"still-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:still-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,90,120,149,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100632712","a-study-on-the-use-of-canakinumab-among-familial-mediterranean-fever-and-stills-disease-patients-100632712",false,"NCT07517250","A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients","Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel","Inclusion criteria:\n\n* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).\n* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.\n\nExclusion criteria:\n\n• Patients Aged \\\u003C2 Years (24 Months) at Index Date.","ALL","1 Year",{"count":19,"type":20},160,"ESTIMATED","OBSERVATIONAL","This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \\[SJIA\\] and adult-onset Still's disease \\[AOSD\\]) that received canakinumab for at least 6 months.",[24,25,26,27],"Familial Mediterranean Fever","Still Disease","Systemic Juvenile Idiopathic Arthritis","Adult-Onset Still Disease",[29,30,31,32,33,34],"Canakinumab","Real-world evidence study","Treatment patterns","Clinical outcomes","Patient quality of life","Pediatric and adult patients","RECRUITING","2026-06-05",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":39},"2026-03-15",{"date":43,"type":20},"2026-12-03",{"name":45,"class":46},"Novartis Pharmaceuticals","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":72,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":47},"100598885","eacvi-study-on-multimodality-cardiovascular-imaging-of-inflammatory-cardiovascular-diseases-100598885","NCT07077304","EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","EACVI-INFLAME","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to provide informed non-opposition\n3. Referred for a CMR and\u002For nuclear imaging exam\n\nAND a suspicion of one of the following ICARDs :\n\n1. Suspected Myocarditis (acute or chronic, and whatever the aetiologies)\n2. Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)\n3. Suspected Tako-Tsubo\n4. Suspected Pericarditis (acute or chronic, and whatever the aetiologies)\n5. Suspected Connective tissue disease with cardiovascular involvement:\n\n   * Systemic sclerosis\n   * Systemic lupus erythematosus\n   * Antiphospholipid syndrome\n   * Idiopathic inflammatory myopathies\n   * Rheumatoid arthritis, spondylarthritis\n6. Suspected Vasculitis with cardiovascular involvement:\n\n   * Small-vessel vasculitis (ANCA…)\n   * Large vessel vasculitis (Behcet disease, Takayasu…)\n7. Suspected Inflammatory disease with cardiovascular involvement:\n\n   * Sarcoidosis\n   * Still disease\n\nExclusion Criteria:\n\n1. Inability to provide non-opposition\n2. History of heart transplant","18 Years",{"count":57,"type":20},5000,"Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity and mortality, independently of traditional risk factors, via multiple pathophysiological mechanisms.\n\nDiagnosis and prognosis are challenged by the heterogeneity of clinical presentations. Multimodality cardiovascular imaging - including cardiovascular magnetic resonance (CMR), transthoracic echocardiography, and positron emission tomography (PET) - plays a central role in detecting and characterizing inflammatory involvement, and may offer prognostic insights.\n\nGiven the limited data on the diagnostic and prognostic utility of these imaging modalities in ICARDs, the EACVI-INFLAME study aims to assess the prevalence of confirmed cardiovascular involvement in patients with suspected or established ICARDs undergoing CMR and\u002For cardiac PET in a multicentric international cohort.",[60,61,62,63,64,65,66,67,68,69,70,25,71],"Myocarditis","ANCA Associated Vasculitis","Pericarditis","Systemic Sclerosis","Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondylarthritis","Behcet Disease","Takayasu Arteritis","Sarcoidosis","Tako Tsubo Cardiomyopathy",[73,74,75,76,77,78,79,80],"Cardiovascular disease","Auto-immune disease","Auto-inflammatory disease","Rheumatic disease","CMR","PET","multimodality imaging","ICARD","2026-06-03",{"date":36,"type":39},{"date":84,"type":39},"2025-11-19",{"date":86,"type":20},"2028-10-30",{"name":88,"class":89},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100640322","phase-3-study-of-the-efficacy-and-safety-of-goflikicept-and-olokizumab-as-the-second-line-therapy-in-patients-with-stills-disease-100640322","NCT07625384","Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease","International Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease","Inclusion Criteria:\n\n1. Voluntarily signed and dated Informed Consent Form (ICF) of the patient agreed to take part in this Study\n2. Confirmed diagnosis of Adult-Onset Still's Disease (AOSD) based on the Yamaguchi M. diagnostic criteria\n3. Patient with active disease or low disease activity per DAVID criteria\n4. In case of current corticosteroid (CS) use, doses must be stable for at least 2 weeks prior to Day 0. The maximum allowed dose of CS is 1 mg\u002Fkg\u002Fday, up to 60 mg\u002Fday (prednisolone equivalent)\n5. In case of current nonsteroidal anti-inflammatory drugs (NSAID) use, dose of NSAIDs must be stable for at least 2 weeks prior to Day 0\n6. In case of current methotrexate (MTX) use, the dose of MTX must be stable for at least 4 weeks prior to Day 0. The maximum allowed dose is 30 mg\u002Fweek. In case of prior MTX discontinuation, it must be performed at least 4 weeks before Day 0\n7. Patient's ability and willingness, in the reasonable opinion of the investigator, to attend the clinical center for all scheduled visits, perform study procedures, and comply with protocol requirements, including consent to receive subcutaneous injections by qualified personnel\n8. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant (excluding women who are post-menopausal, defined retrospectively as 12 months of natural amenorrhea with appropriate clinical status, e.g., age-appropriate), must agree to use highly effective methods of contraception throughout the study, starting from the signing of the ICF until at least 8 weeks after the last dose of study treatment; and must have a negative pregnancy test (serum human chorionic gonadotropin, hCG)\n9. Sexually active male participants must agree to use highly effective methods of contraception throughout the study, starting from the signing of the ICF until at least 8 weeks after the last dose of study treatment\n\nExclusion Criteria:\n\n1. Hypersensitivity to the active and\u002For inactive ingredients of the investigational product\n2. Prior use of the following medications:\n\n   * Rilonacept - less than 6 weeks prior to Day 0\n   * Canakinumab - less than 20 weeks prior to Day 0\n   * Anakinra - less than 1 week prior to Day 0\n   * TNF-alpha inhibitors: etanercept less than 2 weeks, adalimumab, certolizumab, or golimumab less than 10 weeks prior to Day 0\n   * IL-6 inhibitors: olokizumab - less than 20 weeks, tocilizumab - less than 16 weeks, or sarilumab less than 8 weeks prior to Day 0\n   * Janus kinase (JAK) inhibitors - less than 1 week prior to Day 0\n   * Immunosuppressants (azathioprine less than 3 days, cyclosporine less than 1 week, mycophenolate mofetil less than 1 week, tacrolimus less than 10 days, mercaptopurine less than 2 days, etc., except for methotrexate) - less than 5 half-lives prior to Day 0\n   * Leflunomide - less than 10 weeks prior to Day 0\n   * Corticosteroid pulse therapy (e.g., intravenous methylprednisolone 250-1000 mg\u002Fday or equivalent dose of dexamethasone for 3 days) - less than 4 weeks (from the completion of pulse therapy) prior to Day 0\n   * Intravenous immunoglobulin (IVIG) - less than 4 weeks prior to Day 0\n   * Other biologic drug with immunosuppressive effects - less than 5 half-lives prior to Day 0\n3. Use of live-attenuated vaccines within less than 3 months prior to Day 0 (start of the treatment period in the study) and\u002For anticipated need for such vaccination within 3 months after completion of the investigational therapy. Live-attenuated vaccines include vaccines against measles, rubella, mumps, varicella, rotavirus, influenza (intranasal), yellow fever, poliomyelitis (oral polio vaccine), as well as vaccines against tuberculosis (BCG), typhoid (oral typhoid vaccine), and epidemic typhus. Immunocompetent household members of the patient must refrain from receiving oral polio vaccine during the patient's participation in the study\n4. Presence of conditions or signs that, in the investigator's opinion, indicate impaired immune response and\u002For significantly increase the risk associated with immunomodulatory therapy, including but not limited to:\n\n   * Active bacterial, fungal, viral, or protozoal infection at the start of the screening period\n   * Opportunistic infections and\u002For Kaposi's sarcoma at the start of screening\n   * Chronic bacterial, fungal, or viral infection requiring systemic parenteral therapy at the start of screening\n   * HIV infection, viral hepatitis B or C, or syphilis (patients with hepatitis B and\u002For C who have received antiviral therapy and have had undetectable viral load for at least 6 months may be eligible, subject to confirmation by an appropriate specialist)\n5. History of active tuberculosis (TB); suspected or confirmed active tuberculosis at present; or signs of active tuberculosis, including chest computed tomography (CT) or chest X-ray findings consistent with pulmonary tuberculosis during screening; or presence of risk factors for tuberculosis, including but not limited to:\n\n   * Living conditions associated with increased risk of exposure (e.g., correctional facilities, homeless shelters) within 1 year prior to randomization\n   * Healthcare workers with unprotected exposure to patients at high risk of TB or with TB within 1 year prior to randomization\n   * Close contact (i.e., prolonged cohabitation for days or weeks, not minutes or hours) with a person with active tuberculosis within 1 year prior to randomization\n6. History of latent TB without adequate treatment, regardless of screening QuantiFERON-TB\u002FT-SPOT.TB results, or a positive QuantiFERON-TB\u002FT-SPOT.TB result at screening. Such patients may be re-screened and enrolled if all of the following are met:\n\n   * Active TB is ruled out by a certified TB specialist\n   * The patient has completed at least 30 days of prophylactic anti-TB therapy for LTBI prior to screening, using country-recommended regimens\n   * The patient agrees to complete the full course of LTBI treatment\n7. Any other significant comorbidities (cardiovascular, neurological, endocrine, renal, gastrointestinal, hepatic, coagulation disorders, other systemic rheumatic diseases, psychiatric disorders, etc.) that, in the investigator's judgment, may adversely affect participation, patient safety, or study results\n8. History of organ transplantation or need for transplantation at screening\n9. Malignancy during screening or within 5 years prior, except adequately treated non-metastatic basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of any type after complete resection\n10. Pregnancy or breastfeeding\n11. Alcohol or substance abuse, in the investigator's opinion\n12. Severe renal impairment: creatinine clearance (Cockcroft-Gault) \\\u003C 30 mL\u002Fmin\n13. Laboratory abnormalities:\n\n    * Absolute neutrophil count \\\u003C 1.5 × 10\\^9\u002FL\n    * Leukocytes \\\u003C 3.5 × 10\\^9\u002FL\n    * Platelets \\\u003C 100 × 10\\^9\u002FL\n    * Hemoglobin ≤ 80 g\u002FL\n    * HbA1c ≥ 8%\n    * ALT and\u002For AST \\> 8 × ULN\n    * AST and\u002For ALT \\> 3 × ULN with bilirubin \\> 1.5 × ULN\n    * Total bilirubin \\> 2 × ULN (except confirmed Gilbert's syndrome)\n14. Participation in another clinical trial at screening or use of any investigational drug within 4 weeks or 5 half-lives (whichever is longer) prior to Visit 1 (start of treatment period)\n15. Presence or suspicion of macrophage activation syndrome (MAS) at screening. MAS criteria includes persistent fever, splenomegaly, elevated or rising serum ferritin levels, cytopenia, abnormal liver function tests, intravascular activation of coagulation, and elevated or rising serum triglyceride levels\n16. Diagnosis of MAS within 2 months prior to Day 0\n17. Prior participation in this clinical study, provided the patient received at least one dose of the investigational product",{"count":98,"type":20},52,"INTERVENTIONAL",[101],"PHASE3","The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease",[25],[105,106,107,108],"Still's Disease","Goflikicept","RPH-104","Olokizumab","NOT_YET_RECRUITING","2026-05-28",{"date":112,"type":39},"2026-06-04",{"date":114,"type":20},"2026-05-18",{"date":116,"type":20},"2028-07-01",{"name":118,"class":46},"R-Pharm International, LLC",25,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":47},"100510516","acostill--radico-cohort-radico-acostill-100510516","NCT05927454","Acostill ( RaDiCo Cohort) (RaDiCo Acostill)","Cohorte d'Adultes et d'Enfants Avec Maladie de Still","Acostill","Inclusion Criteria:\n\n* Aged over 16 (age\\> 16) meeting the diagnostic criteria of Yamaguchi or Fautrel criteria (appendix 5)\n* Aged 16 years or less (age ≤16 years) fulfilling the 2001 criteria for ILAR systemic form of juvenile idiopathic arthritis\n* Having signed a consent to participate in the cohort and in the collection of clinical and biological data; in accordance with the regulations, for patients who are minors or adults who are protected, the non-opposition of the legal representatives will be sought.\n* Affiliated to the \"Régime National d'Assurance Maladie\".\n\nExclusion Criteria:\n\n* Other cause of relapsing infectious fever (such as tuberculosis, toxoplasmosis, deep abscesses, viroses, sepsis) or tumor (such as lymphomas)\n* Other defined inflammatory rheumatism such as rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies.\n* Autoimmune inflammatory disease (systemic lupus erythematosus), granulomatosis (sarcoidosis, Blau syndrome), vasculitis (Behçet's disease, nodular arteritis), polymyositis and dermatomyositis.\n* Well-defined auto-inflammatory syndromes with unambiguous mutations, such as familial Mediterranean fever, cryopyrinopathies, TRAPS, mevalonate kinase deficiency.\n* Known macrophage activation syndromes of genetic origin.\n* Patients unable to understand the information leaflet and sign the informed consent form\n* Patients not affiliated to the \"Régime National d'Assurance Maladie\"",{"count":129,"type":20},500,"Adult Onset Still Disease (AOSD) and Systemic onset Juvenile Idiopathic Arthritis (SoJIA) are two rare multifactorial diseases associated with systemic inflammation. These two forms AOSD and SoJIA are considered to be two facets of the same syndrome, combining four cardinal symptoms \\[hectic fever\\> 39 °, arthralgia or arthritis, skin rash, a leukocyte formula with more than 80% of neutrophils\\]; lymphadenopathy and splenomegaly may also be found. There is an important biological inflammatory syndrome with elevation of the reactive C protein, of serum ferritin with a dramatic drop in the glycosylated fraction. The incidence of the disease is low, around 0.1\u002F100,000 for adults and 0.6\u002F100,000 for children. Its prevalence is approximately 1 to 3\u002F100,000 and 3\u002F100,000 for children, so there are approximately 500 to 1,500 adults and 450 children affected in France. It is subdivided into pediatric and adult forms according to the age of onset before or after 16 years. The prognosis of the disease is functional and vital. Macrophage activation syndrome (SAM) is frequently associated with either the onset of the disease or the initiation of treatment or concomitantly with viral reactivation. The course over time has mainly been studied in children and is variable: regression, course by flare-ups with term regression and chronic joint development. In adults we can also observe these 3 evolutionary modes. However, differences seem to exist between AOSD and SoJIA.\n\nThe various clinical questions posed by this disease are as follows:\n\n* Why does it differentially affect two age groups of the population?\n* Why is the clinical expression heterogeneous with pure systemic or articular forms, the frequency of SAM, and rare organ damage?\n* Why is the evolution over time different with resolving monocyclic forms or polycyclic forms and sometimes chronic evolutions?\n\nThese differences could be explained by distinct underlying pathogenic mechanisms. But at present, the pathophysiology of this entity remains unknown, although several hypotheses can be formulated involving several pathophysiological pathways.\n\nThe pathogenesis of Still's disease has not yet been elucidated but there is a significant inflammatory reaction without the production of autoantibodies, which makes this disease a form of autoinflammatory syndrome with abnormalities of the innate immunity (activation of macrophages, strong elevations of pro-inflammatory cytokines: interleukins 1 and 18, possible abnormalities of inflammasomes and NK cells). The treatment is based on anti-inflammatory drugs, corticosteroids with the usefulness of methotrexate and anti-TNF in the event of significant joint damage. Interleukin 1 and 6 inhibitors have been shown to be effective in this disease. In adults and children, there are forms that are refractory to treatment, with a risk of AA amyloidosis for these patients.\n\nThe expected outcomes of this work are to improve knowledge of Still disease and patient management on the following aspects:\n\n* Comparison of pediatric and adult forms (which has never been done on a large number of patients),\n* Better understanding of the pathogenic mechanisms of the disease,\n* The identification of early diagnostic\u002Fprognostic markers,\n* The possibility of promoting the evaluation of new therapies to come thanks to the constitution of an active file of patients with a standardized follow-up.\n\nThe ACOSTILL study group is thus a unique collaboration of adult clinicians (rheumatologists and internists) and pediatricians, who have decided to unite their efforts to increase knowledge about the pathogenesis of Still disease in order to better understand the disease and improve care pathways. Many of them participated in the development of the national diagnostic and care protocol published in 2018.",[25,132,133],"Still's Disease, Adult-Onset","Still Disease, Juvenile Onset",[25,135,136,137,138],"Rare disease","Diagnostic markers","Prognostic markers","New therapies","2026-02-10",{"date":141,"type":39},"2026-02-12",{"date":143,"type":39},"2017-07-11",{"date":145,"type":20},"2027-07",{"name":147,"class":148},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":156,"enrollmentInfo":157,"targetDuration":159,"studyType":21,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100602640","clinical-autoinflammatory-disease-cohort-100602640","NCT07126145","Clinical Autoinflammatory Disease Cohort","CAID","Inclusion Criteria:\n\n* Diagnosis of adult-onset Still's disease (AOSD) according to the Yamaguchi criteria (as described above) or other established autoinflammatory disease diagnostic criteria.\n* Age between 18 and 75 years, inclusive.\n* Willingness and ability to comply with scheduled follow-up visits, examinations, and treatments.\n* Voluntary provision of written informed consent.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent; age under 18 or over 75 years; inability to provide at least 80% of the required core data for Still's disease or other autoinflammatory diseases.\n* Presence of other connective tissue diseases.\n* Positive detection of autoantibodies.\n* Current acute infection or history of active tuberculosis.\n* History of allergic constitution or multiple drug allergies.\n* Psychiatric disorders or other conditions preventing compliance with examinations, follow-up, or treatment.\n* Women who are currently pregnant or planning to become pregnant.\n* Presence of malignant tumors.\n* Participation in other clinical trials currently or within a specified washout period.","75 Years",{"count":158,"type":20},1000,"12 Months","Autoinflammatory diseases (AIDs) are a group of rare disorders caused by dysregulation of the innate immune system, characterized by recurrent fever, systemic inflammation, and involvement of specific organs. Diagnosis relies on a combination of clinical features, laboratory tests, genetic findings, and response to treatment. Still's disease is a representative type of AID, marked by high spiking fevers, polyarthritis, evanescent rash, and markedly elevated inflammatory markers. Among its complications, macrophage activation syndrome (MAS) is the most life-threatening, affecting approximately 10-15% of patients. MAS involves uncontrolled immune activation and systemic inflammation, and if left untreated, may result in a mortality rate exceeding 50%. This study aims to develop a standardized clinical dataset and diagnostic-treatment framework for AIDs based on their disease characteristics. After establishing a data collection template, eligible patients aged 18-75 years with AIDs will be enrolled. Clinical data will be collected to build a prospective follow-up cohort, focusing particularly on adult-onset Still's disease (AOSD), to explore the clinical features and pathogenesis of AIDs.",[25,162],"Autoinflammatory Disease","2025-08-10",{"date":165,"type":39},"2025-08-17",{"date":167,"type":20},"2025-08",{"date":169,"type":20},"2035-08",{"name":171,"class":89},"RenJi Hospital",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":180,"targetDuration":182,"studyType":21,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":181,"type":20},3500,"10 Years","Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[185,186,187,188,25,189,190,191,192,193,194],"Hereditary Autoinflammatory Diseases","Schnitzler Syndrome","Behcet Syndrome","PFAPA Syndrome","Autoinflammatory Syndrome, Unspecified","Uveitis","Scleritis","Vexas Syndrome","Spondyloarthritis (SpA)","Castleman Disease","2025-07-07",{"date":197,"type":39},"2025-07-10",{"date":199,"type":39},"2020-08-06",{"date":201,"type":20},"2030-08-06",{"name":203,"class":89},"University of Siena",112]